OSU Co-Anchors National Precision Cancer Research Collaboration
Pelotonia funds have enabled the OSUCCC – James to extend its reach by helping to establish the Oncology Research Information Exchange Network (ORIEN).
Founded and co-anchored by Moffitt Cancer Center in Tampa, Fla., and the OSUCCC – James, ORIEN is a national collaboration involving nine cancer centers that are using a protocol called Total Cancer Care® (TCC) to hasten the development and delivery of more precise cancer treatments, diagnostic tools and prevention strategies through secure research-sharing of consented patient data.
Other ORIEN members are Rutgers Cancer Institute of New Jersey, University of Virginia Health System, Morehouse School of Medicine in Atlanta, University of New Mexico Cancer Center, University of Southern California (USC) Norris Comprehensive Cancer Center, City of Hope National Medical Center in Duarte, Calif., and University of Colorado Cancer Center.
The TCC protocol is a lifetime partnership between cancer patients and their treatment institution in which patients consent to donate their de-identified tissue and clinical data, including corresponding genomic data, for research. ORIEN member institutions then share that data to help them better understand cancer at the molecular level and accelerate the development of more targeted treatments for individual patients. As of last summer, more than 124,000 patients had consented to the TCC protocol.
Saving More Lives Statewide: An Update
Through the Pelotonia-funded Ohio Colorectal Cancer Prevention Initiative (OCCPI), the OSUCCC – James is now working with 50 Ohio hospitals to reduce the number of deaths from colorectal cancer (CRC) in a statewide screening initiative.
The OCCPI, led by Heather Hampel, MS, LGC, of the OSUCCC – James, focuses on screening tumor samples from CRC patients to learn which ones also have Lynch syndrome (LS), a cancer-causing condition that occurs when a person inherits a mutation in one of four genes. Anyone who has one of those mutations is very likely to develop CRC, uterine, ovarian or other cancer.
First-degree relatives (parents, siblings and children) of someone with LS have a 50-percent chance of inheriting the same mutation. But when LS is identified in one family member, other members can be tested for the mutation. Those found to have LS are counseled to seek regular screening to prevent cancer or detect it early.
Pelotonia has provided the OCCPI with $3.5 million in support. By September 2015, the OCCPI had identified LS or other hereditary cancer syndromes in more than 150 individuals. The OCCPI is expected to produce $36.85 million in community benefit and save an estimated 737 life years.